Singapore, Oct. 21 -- Japan's Chugai Pharmaceutical and US-based Rani Therapeutics, LLC, a subsidiary of Rani Therapeutics Holdings, Inc., have entered into a Collaboration and License Agreement for the development and commercialisation of an oral product consisting of Rani's oral delivery technology, the RaniPill(R), and Chugai's rare disease antibody in development.

Published by HT Digital Content Services with permission from BioSpectrum Asia....